Compare BTAI & FOXX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | BTAI | FOXX |
|---|---|---|
| Founded | 2017 | 2017 |
| Country | United States | United States |
| Employees | 37 | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | |
| Sector | Health Care | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 35.6M | 34.0M |
| IPO Year | 2018 | N/A |
| Metric | BTAI | FOXX |
|---|---|---|
| Price | $1.59 | $4.71 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 3 | 0 |
| Target Price | ★ $26.67 | N/A |
| AVG Volume (30 Days) | ★ 296.9K | 9.2K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $261.81 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.17 | $1.71 |
| 52 Week High | $8.08 | $8.70 |
| Indicator | BTAI | FOXX |
|---|---|---|
| Relative Strength Index (RSI) | 45.49 | 47.96 |
| Support Level | $1.50 | $4.48 |
| Resistance Level | $1.72 | $4.80 |
| Average True Range (ATR) | 0.10 | 0.40 |
| MACD | 0.01 | -0.04 |
| Stochastic Oscillator | 24.53 | 34.14 |
BioXcel Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is focused on drug development utilizing novel artificial intelligence (AI) to identify the next wave of medicines across neuroscience and immuno-oncology. The pipeline products of the company are BXCL501 and BXCL701. The company's commercial product, IGALMI (developed as BXCL501) is a proprietary, sublingual film formulation of dexmedetomidine approved by the FDA for the acute treatment of agitation associated with schizophrenia or bipolar I or II disorder in adults.
Foxx Development Holdings Inc is a consumer electronics and integrated Internet-of-Things (IoT) solution company catering to both retail and institutional clients. With robust research and development capabilities and a strategic commitment to cultivating long-term partnerships with mobile network operators, distributors, and suppliers. Its products include tablets, smartphones, wearables, and other high-quality communication terminals. The company's current revenue stream is derived from the sales of tablets and smartphones.